Back to Studies

Study analysis · PLoS ONE · 2016

The Mediterranean diet cut heart attacks and strokes by 37% in a major meta-analysis — but the same study found no clear benefit for living longer, and one large trial was so questionable that removing it erased some benefits.

A Mediterranean-style diet may lower the relative risk of heart attacks and strokes in people at high risk, but this review found no clear reduction in death and the evidence is shaky.

Reading level
Low certainty
Level 1a · Systematic review of RCTsAssociation, not causationNo causal claims

Overview

What the study found

The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.

In simple terms

This study combined several randomized trials, which is usually the best way to test if something causes an effect. But the trials had problems, and one was unreliable, so we can't be sure the Mediterranean diet actually causes better heart health—it might just be linked.

What’s the bottom line?

Researchers combined six studies to see if a Mediterranean diet helps prevent heart problems and death compared to other diets.

How strong is this study?

The researchers did a good job searching and combining the studies, but the original trials weren't very strong. Some weren't blinded, and one was even suspected of being fake, so the results are uncertain and should be taken with caution.

Reporting

0 / 100

  • COI disclosureconflicts of interest not disclosed
  • Data availabilitydata not shared
  • Code availabilitycode not shared
Methodology

38 / 100

  • Randomizationnot randomized
  • Blindingnot blinded
  • Control groupno control group
  • Sample size (n=10950)+20/20
  • Follow-up+10/10
Publication

100 / 100

Statistical

77 / 100

  • P-values+15/15
  • Effect size+20/20
  • Confidence intervals+15/15
  • Pre-registrationnot pre-registered

Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.

Where it sits

RCT reviews

Max 100

Randomized Trials

Max 90

Reviews of Cohort Studies

Max 85

Cohort Studies

Max 72

Reviews of Case-Control Studies

Max 63

Case-Control Studies

Max 58

Cross-Sectional & Case Series

Max 50

Expert Opinion

Max 5
StrongerWeaker
Reviews of RCTs (Meta-analyses)
Level 1a
52

52 / 100

Probability of being correct

The highest quality evidence. Systematic reviews and meta-analyses that pool randomized controlled trials, giving the most reliable summary of experimental evidence.

This design cannot establish causation — the findings describe an association, not a cause. Although the study is a systematic review and meta-analysis of RCTs (Level 1a), the actual evidence base is limited by high risk of bias (no double-blinding, incomplete outcome assessment blinding), small number of trials, few events, heterogeneity, and serious data integrity concerns for one large trial. The review itself concludes that the evidence falls short of that required for definitive causal conclusions. Therefore, causation cannot be established from this study.

No Conflicts

No conflicts of interest identified

No conflicts of interest or funding disclosures were present in the provided text; the study appears to be an independent systematic review.

The provided text is truncated and does not include a competing interests or funding section. One included study (Singh et al 2002) was noted to have serious concerns about data integrity, but this is not an author conflict of interest.

Key takeaways

  1. 01

    Major heart/vascular events: 37% lower relative risk (RR 0.63); after removing a questionable study, 31% lower relative risk (RR 0.69).

  2. 02

    Stroke: 35% lower relative risk (RR 0.65).

  3. 03

    All-cause death: no clear difference (RR 1.00).

  4. 04

    Heart-related death: no clear difference (RR 0.90).

  5. 05

    Absolute risk difference was not reported; pooled major event rate was about 5.3% (477 events in 9,052 people) over different follow-up times.

  6. 06

    The study did not report how much the diet changed absolute risk, so we cannot say how many extra or fewer cases per 1,000 people.

  7. 07

    The pooled event rate was about 5.3% for major cardiovascular events across trials of varying length, but without a control-group baseline we cannot calculate absolute benefit.

  8. 08

    The relative reductions sound large, but the evidence is weak and one large trial was questioned.

Surprising findings

  • No clear reduction in all-cause or cardiovascular mortality despite a reduction in major cardiovascular events.Most people assume a heart-healthy diet should also help you live longer, but the mortality confidence intervals included no difference.
  • A 70% relative reduction in heart failure disappeared after excluding one questionable trial.Such a large effect would be practice-changing, but it was based on only 56 events and became non-significant when the Singh trial was removed.
  • One large trial included in the meta-analysis had serious data-integrity concerns.The trial contributed 145 major cardiovascular events and heavily influenced pooled estimates, yet its veracity was significantly doubted.
  • Greater benefits were seen in small, single-centre studies with incomplete follow-up.This pattern often suggests bias or overestimation rather than a true biological effect.

Practical takeaways

If you are at increased cardiovascular risk, a Mediterranean-style diet may lower your relative risk of major cardiovascular events and stroke, but do not expect it to clearly extend lifespan based on this meta-analysis.

Absolute risk reduction was not reported, and the evidence quality is limited by lack of blinding, few events, and one questionable trial.

low confidence

Focus on the overall dietary pattern: olive oil as main cooking fat, nuts, legumes, whole grains, fruits, vegetables, fish, moderate red wine, and less red meat and dairy.

The meta-analysis did not test individual components, and no adverse event data were available.

medium confidence

Be skeptical of headlines claiming a 37% reduction in heart attacks or strokes. Ask for the absolute risk difference and whether the result held after excluding questionable studies.

Relative risk reductions can be large while absolute benefits remain small or unknown.

high confidence

Do not stop or change prescribed cardiovascular medications based on this study. Discuss dietary changes with your clinician.

This meta-analysis did not compare diet against medication and cannot prove that diet replaces drug therapy.

high confidence

Why this study matters

37% Relative Reduction in Major Cardiovascular Events

Pooled analysis of 3 RCTs with 9,052 participants and 477 events found a relative risk of 0.63 (95% CI 0.53–0.75), a 37% relative reduction in major cardiovascular events. After excluding a trial with serious data-integrity concerns, the relative risk was 0.69 (95% CI 0.55–0.86), a 31% relative reduction. The absolute risk difference was not reported; the pooled event rate was about 5.3% (477/9,052) over varying follow-up.

This is the headline number everyone will cite, but without absolute risk it is impossible to say how many people actually benefited.

Stroke Benefit Holds Up

For stroke, the pooled relative risk was 0.65 (95% CI 0.48–0.88), a 35% relative reduction across 3 RCTs. After excluding the questionable trial, the relative risk was 0.66 (95% CI 0.48–0.92), a 34% relative reduction, making stroke one of the more robust findings. Absolute risk difference was not reported.

Stroke is one of the most feared cardiovascular outcomes, and this benefit persisted even after removing a major source of doubt.

No Clear Mortality Benefit

All-cause mortality showed no clear effect: relative risk 1.00 (95% CI 0.86–1.15) across 5 RCTs with 10,671 participants and 693 deaths. Cardiovascular mortality was also not clearly reduced: relative risk 0.90 (95% CI 0.72–1.11) across 4 RCTs with 10,623 participants and 315 cardiovascular deaths. Absolute risk differences were not reported.

Many people adopt the Mediterranean diet specifically to live longer, yet this meta-analysis found no clear mortality benefit.

Fragile Findings: Coronary Events and Heart Failure Vanish

Coronary events initially showed a relative risk of 0.65 (95% CI 0.50–0.85), a 35% relative reduction, but after excluding the questionable trial it became non-significant (RR 0.73, 95% CI 0.51–1.05). Heart failure initially showed a relative risk of 0.30 (95% CI 0.17–0.56), a 70% relative reduction, but this was based on only 56 events and disappeared after exclusion (RR 0.25, 95% CI 0.05–1.17). Absolute risk differences were not reported.

It shows how one large trial can drive dramatic results, and how quickly benefits can evaporate when data integrity is questioned.

One Large Trial Had Serious Data-Integrity Concerns

The Singh et al. trial (n=1,000, 145 major cardiovascular events) had serious concerns about the integrity of its data. The authors note that if the Mediterranean diet were seeking regulatory approval, the data from this trial would likely be ineligible. Excluding it changed key findings.

It raises uncomfortable questions about the evidence base behind a widely recommended diet.

Evidence Base Is Weak: No Double-Blinding, Few Events, No Adverse Events

Six RCTs with 10,950 participants were included, but no trial was double-blinded, only 3 had blinded outcome assessment, and there was high risk of bias, heterogeneity, and few events. No data were available on adverse events, new-onset type 2 diabetes, or end-stage kidney disease.

Clinical guidelines recommend the Mediterranean diet, yet the randomized evidence for hard outcomes is limited and fragile.

Want the whole report?

Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.

Standing

Who’s using this study?

The videos and claims on this site that lean on this study, and the researchers who wrote it.

1 video from Dr Brad Stanfield cite this study, drawing 1 claim from it.

Dr Brad Stanfield
We Are Witnessing The End of Heart Attacks
Citing claim
Supports
All 1 video reference this study through extracted claims.

Authored by

9 researchers

If this is your work, this is how we attribute it on Fit Body Science. Thaminda Liyanage is listed as the lead author.